Drugs Made In America Acquisition Corp. Ordinary Shares
NASDAQ:DMAAShell Companies
+$0.00 today
- Market cap
- $264.62M
- Beta
- 0.00
- P/E (TTM)
- 36.7
- EPS (TTM)
- $0.29
Volume 0.00M
Average 0.11M
DMAA Operating Expenses
Total costs of running the business that are not directly tied to producing goods or services sold.
Drugs Made In America Acquisition Corp. Ordinary SharesNASDAQ: DMAA
Operating Expenses · Q1 FY2026 · quarter ended Mar 2026
Operating expenses dips below year-ago levels
Q1 FY2026 operating expenses of $143.3K fell 56.7% year over year, behind the +452.0% change in trailing-twelve-month operating expenses. Sequentially, it fell 93.1% from the prior quarter.
What to watch
Whether quarterly growth recovers from -56.7% toward the trailing-twelve-month pace of +452.0%.
Sources:Income StatementText generated from reported figures; not investment advice.
Operating Expenses history
USD · from the income statement
- Latest · FY2025
- 2.82M USD
- Year-over-year change
- +586894.7%
- 1-year CAGR
- +586894.7%
| Period | Period end | Operating Expenses | YoY change |
|---|---|---|---|
| FY2025 | 2025-12-31 | 2.82M | +586894.7% |
| FY2024 | 2024-12-31 | 480 | — |
Operating Expenses vs competitors
How DMAA compares with its peers on the latest reported figures
- DMAA's LTM Mar 2026 operating expenses of $2.63M is the 2nd highest of the 10 companies compared; the peer median is $1.11M.
- Its year-over-year change of +452.0% is the 2nd highest of 5, against a peer median of +132.4%.
| Company | Period | LTM | YoY | 3-year CAGR | % of revenue |
|---|---|---|---|---|---|
| LTM Mar 2026 | $3.06M | — | — | — | |
| LTM Mar 2026 | $2.63M | +452.0% | — | — | |
TACHTitan Acquisition Corp. | LTM Mar 2026 | $1.69M | +667097.0% | — | — |
| LTM Mar 2026 | $1.37M | +251.8% | -9.5% | — | |
| LTM Mar 2026 | $1.31M | — | — | — | |
TACOUBerto Acquisition Corp. Unit | LTM Mar 2026 | $1.11M | — | — | — |
| LTM Mar 2026 | $1.11M | — | — | — | |
| LTM Mar 2026 | $891.28K | +13.0% | — | — | |
OYSEOyster Enterprises II Acquisition Corp | LTM Mar 2026 | $599.68K | — | — | — |
| LTM Mar 2026 | -$149.87K | -104.8% | — | — | |
| Peer median (excluding DMAA) | $1.11M | +132.4% | -9.5% | — | |
Competitors are the stored peer set for DMAA. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.
Income Statement
Metric | FY2024 Dec 2024 | FY2025 Dec 2025 |
|---|---|---|
| Revenue | 0 | 0 |
| Cost of Revenue | 0 | 0 |
| Gross Profit | 0 | 0 |
| Gross Margin | — | — |
| Research & Development | 0 | 0 |
| Selling, General & Admin | 480 | 2.82M |
| Operating Expenses | 480 | 2.82M |
| Depreciation & Amortization | 480 | 0 |
| EBITDA | (279.85K) | (2.82M) |
| EBITDA Margin | — | — |
| Operating Income | (479) | (2.82M) |
| Operating Margin | — | — |
| Interest Income | 0 | 8.76M |
| Interest Expense | 0 | 0 |
| Other Income / Expenses | 0 | 8.76M |
| Income Before Tax | (479) | 5.94M |
| Pre-Tax Margin | — | — |
| Income Tax Expense | 0 | 0 |
| Net Income | (479) | 5.94M |
| Net Margin | — | — |
| EPS (Basic) | (0.06) | 0.19 |
| EPS (Diluted) | (0.06) | 0.19 |
| Weighted Avg Shares | 8.57M | 21.01M |
| Weighted Avg Shares (Diluted) | 8.57M | 21.01M |
Drugs Made In America Acquisition Corp. Ordinary Shares
NASDAQ:DMAA
Intrinsic Alpha fair value
Locked
Current Price
$10.90
Unlock the intrinsic value to see where the current price sits on the valuation runway.
Valuation runway
LockedGet the intrinsic value and margin of safety with a free account.
Continue the stock analysis
Jump to another research area for this company.